Table 2.
Clinical and Genetic Characteristics of HCM Patients
| Clinical | |
| NYHA functional class | |
| I | 38 (76) |
| II | 10 (20) |
| III | 2 (4) |
| IV | 0 (0) |
| NSVT | 15 (30) |
| Unexplained syncope | 3 (6) |
| Family history of SCD | 7 (14) |
| Massive LVH ≥30 mm | 0 (0) |
| Abnormal exercise BP response | 5 (10) |
| SCD risk factors | |
| 0 | 23 (46) |
| 1 | 24 (48) |
| 2 | 3 (6) |
| 3 | 0 (0) |
| ESC HCM Risk-SCD score | 2.6 (1.2–8.7) |
| Genetic | |
| No pathogenic variant | 20 (40) |
| MYBPC3 | 17 (34) |
| MYH7 | 12 (24) |
| Troponin I | 1 (2) |
Values are n (%) or median (range).
BP = blood pressure; ESC = European Society of Cardiology; HCM = hypertrophic cardiomyopathy; LVH = left ventricular hypertrophy; NSVT = nonsustained ventricular tachycardia; NYHA = New York Heart Association; MYBPC3 = myosin-binding protein C; MYH7 = beta-myosin heavy chain; SCD = sudden cardiac death.